CBTRUS Statistical Report on Brain tumours

The paper was recently published in Neuro-Oncology. I have included the salient updates here.

Access it here

Ostrom, Quinn T., Gino Cioffi, Kristin Waite, Carol Kruchko, and Jill S. Barnholtz-Sloan. n.d. “CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018.” https://doi.org/10.1093/neuonc/noab200#supplementary-data.

• The objective of the CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018 is to provide a comprehensive summary of the current descriptive epidemiology of primary brain and other central nervous system (CNS) tumors in the United States (US) population
• This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy and is the first CBTRUS Report to provide the distribution of molecular markers for selected brain and CNS tumor histologies
• The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.25 (Malignant AAAIR=7.06, Non-malignant AAAIR=17.18). This overall rate was higher in females compared to males (26.95 versus 21.35) and non-Hispanics compared to Hispanics (24.68 versus 22.12)
• Glioblastoma was more common in males, and meningioma was more common in females
• An estimated 88,190 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2021 (25,690 malignant and 62,500 non-malignant)
• There were 83,029 deaths attributed to malignant brain and other CNS tumors between 2014 and 2018
• The CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018 contains the most up-to-date population-based data on primary brain tumors available through the surveillance system in the US and supersedes all previous reports in terms of completeness and accuracy, thereby providing a current comprehensive source for the descriptive epidemiology of these tumors. This is the first CBTRUS Report to provide the distribution of molecular markers for selected brain and CNS tumor histologies
• The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.25 per 100,000 between 2014 and 2018. This overall rate was higher in females compared to males (26.95 versus 21.35 per 100,000) and non-Hispanics compared to Hispanics (24.68 versus 22.12 per 100,000)
• Incidence was higher in females compared to males (6.33 versus 6.10 per 100,000), Whites compared to Blacks (6.42 versus 4.87 per 100,000), and non-Hispanics compared to Hispanics (6.50 versus 5.35 per 100,000)
• There were 83,029 deaths attributed to malignant brain and other CNS tumors between 2014 and 2018 This represents an average annual mortality rate of 4.43 per 100,000, and an average of 16,606 deaths per year caused by malignant brain and other CNS tumors
• Incidence counts and rates of primary malignant and non-malignant brain and other CNS tumors are presented by histology, sex, age, race, Hispanic ethnicity, and geographic location
• This report is the first CBTRUS annual Statistical Report to provide the distribution of molecular markers for selected brain and CNS tumor histologies
• This report represents the twenty-ninth (29th) anniversary of CBTRUS and the twenty-fourth (24th) statistical report published by CBTRUS. For this tenth (10th) report published as a Supplement to Neuro-Oncology, the official journal of the Society for Neuro-Oncology, CBTRUS continues its past efforts to provide the most up-to-date population-based incidence rates for all primary brain and other CNS tumors by behavior, histology, age, sex, race, and Hispanic ethnicity. These data have been organized by clinically relevant histology groupings and reflect the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System
• These data have been organized by clinically relevant histology groupings and reflect the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System.2. These data provide important information for allocation and planning of specialty healthcare services such as clinical trials, disease prevention and control programs, and research activities. These data may lead to clues that will stimulate research into the causes of this group of diseases, which often result in significant morbidity and mortality
• Means, medians, rates, ratios, proportions, and other relevant statistics were calculated using R 4.0 statistical software30 and/or SEER*Stat 8.3.9.31 Figures and tables were created in R 4.0.5 using the following packages: flextable, officer, orca, plotly, SEER2R, sf, survminer, tigris, and tidyverse
• Rates are suppressed when counts are fewer than 16 within a cell but included in totals, except when data are suppressed from only one cell to prevent identification of the number in the suppressed cell
• NOTE: reported percentages may not add up to 100% due to rounding
• The 0–14 years age group is a standard age category for childhood cancer used by other cancer surveillance organizations and has been included in this report for consistency and comparison purposes
• Other race, unspecified, and unknown race are included in statistics that are not race-specific
• This report aims to serve as a useful resource for researchers, clinicians, patients, and families
• In keeping with its mission, CBTRUS has revised its histology grouping to be consistent with the 2016 WHO classification and presents clinically relevant biomarker data for the first time